Compare Infosys Limited (INFY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Zimmer Biomet Holdings Inc — how do they compare? Infosys Limited trades at $11.25 (market cap $46.65B), while Zimmer Biomet Holdings Inc trades at $89.74 (market cap $17.36B). The key difference: Infosys Limited is far larger — about 2.7× Zimmer Biomet Holdings Inc's market cap, and Infosys Limited pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| INFY | ZBH | |
|---|---|---|
Market Cap | $46.65B | $17.36B |
Sector | Technology | Health |
52-Week High | $20.22 | $107.71 |
52-Week Low | $10.49 | $79.58 |
Enterprise Value | $43.87B | $24.40B |
Dividend Yield | 4.63% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.31, down 1.57% on the day, with a bullish technical signal despite bearish moving averages. The stock shows strong profitability with a 16.44% net income margin and 31.57% ROE, supported by recent earnings beats. Recent news highlights AI collaborations with firms like Sentara and GlobalFoundries, positioning the company for growth in enterprise AI services.
The outlook is cautiously optimistic with a consensus price target of $12.28, implying 8.6% upside. Risks include competitive pressures in IT services and potential volatility from sector-wide demand concerns, as seen with Accenture's recent outlook. Analyst sentiment is mixed, with 37.5% buy ratings but a majority hold stance, reflecting balanced near-term expectations.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
